Taysha Gene Therapies, Inc. (TSHA)

NASDAQ: TSHA · Real-Time Price · USD

4.700

-0.090 (-1.88%)

At close: Feb 20, 2026, 4:00 PM EST

4.770

+0.069 (1.48%)

After-hours: Feb 20, 2026, 5:22 PM EST

Taysha Gene Therapies Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 20, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	1,287	355	331	141	448	1,002
Market Cap Growth	271.71%	7.14%	134.50%	-68.52%	-55.28%	-
Enterprise Value	1,059	260	227	170	314	724
Last Close Price	4.70	1.73	1.77	2.26	11.65	26.54
PS Ratio	204.03	42.55	21.42	56.40	-	-
PB Ratio	5.88	4.96	4.42	148.70	4.70	3.99
P/TBV Ratio	5.88	4.96	4.42	148.70	4.70	3.99
EV/Sales Ratio	167.85	31.19	14.67	67.98	-	-
Debt / Equity Ratio	0.32	0.89	0.82	63.15	0.66	-
Net Debt / Equity Ratio	-1.04	-1.05	-1.10	-29.45	-0.90	-1.00
Net Debt / EBITDA Ratio	2.26	0.88	1.18	0.22	0.50	5.84
Net Debt / FCF Ratio	2.68	0.93	1.08	0.26	0.65	8.15
Asset Turnover	0.03	0.05	0.10	0.02	-	-
Quick Ratio	10.39	5.30	3.92	1.40	2.88	35.24
Current Ratio	10.48	5.42	4.08	1.54	3.08	36.17
Return on Equity (ROE)	-64.93%	-121.94%	-294.04%	-344.67%	-100.68%	-47.79%
Return on Assets (ROA)	-25.70%	-32.51%	-29.84%	-46.30%	-45.80%	-20.76%
Return on Capital Employed (ROCE)	-35.50%	-64.60%	-52.50%	-198.50%	-106.80%	-17.10%
Earnings Yield	-7.76%	-25.19%	-33.71%	-117.64%	-38.94%	-5.99%
FCF Yield	-6.61%	-23.02%	-23.23%	-77.25%	-29.53%	-3.07%
Buyback Yield / Dilution	-26.22%	-115.41%	-164.20%	-16.74%	-113.13%	-83.53%

Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q